Bal Pharma Limited – NSE:BALPHARMA.NS
Bal Pharma Limited stock price today
Bal Pharma Limited stock price monthly change
Bal Pharma Limited stock price quarterly change
Bal Pharma Limited stock price yearly change
Bal Pharma Limited key metrics
Market Cap | 1.96B |
Enterprise value | 3.47B |
P/E | 25.55 |
EV/Sales | 1.07 |
EV/EBITDA | 10.01 |
Price/Sales | 0.59 |
Price/Book | 2.84 |
PEG ratio | 0.25 |
EPS | 4.94 |
Revenue | 3.38B |
EBITDA | 326.10M |
Income | 85.03M |
Revenue Q/Q | 14.76% |
Revenue Y/Y | 11.43% |
Profit margin | 2.36% |
Oper. margin | 6.67% |
Gross margin | 34.7% |
EBIT margin | 6.67% |
EBITDA margin | 9.62% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBal Pharma Limited stock price history
Bal Pharma Limited stock forecast
Bal Pharma Limited financial statements
| Jun 2023 | 701.65M | 11.95M | 1.7% |
|---|---|---|---|
| Sep 2023 | 925.42M | 9.45M | 1.02% |
| Dec 2023 | 816.63M | 8.88M | 1.09% |
| Mar 2024 | 946.26M | 54.73M | 5.78% |
| Payout ratio | 0% |
|---|
| 2016 | 1.17% |
|---|---|
| 2017 | 1.36% |
| 2019 | 1.46% |
| 2020 | 3.13% |
| 2022 | 0.93% |
| Jun 2023 | 0 | 0 | |
|---|---|---|---|
| Sep 2023 | 3298393000 | 2.66B | 80.84% |
| Dec 2023 | 0 | 0 | |
| Mar 2024 | 3203890000 | 2.51B | 78.38% |
| Mar 2023 | 41.73M | 0 | 0 |
|---|---|---|---|
| Jun 2023 | 50.68M | 0 | 0 |
| Sep 2023 | 48.38M | 0 | 0 |
| Dec 2023 | 59.25M | 0 | 0 |
Bal Pharma Limited alternative data
| Aug 2023 | 837 |
|---|---|
| Sep 2023 | 837 |
| Oct 2023 | 869 |
| Nov 2023 | 869 |
| Dec 2023 | 869 |
| Jan 2024 | 869 |
| Feb 2024 | 869 |
| Mar 2024 | 869 |
| Apr 2024 | 869 |
| May 2024 | 869 |
| Jun 2024 | 869 |
| Jul 2024 | 869 |
Bal Pharma Limited other data
| Insider | Compensation |
|---|---|
Mr. Shailesh Dheerajmal Siroya (1966) MD & Executive Director | $10,200,000 |
Mr. Himesh Virupakshaya (1961) Whole Time Director | $3,050,000 |
-
What's the price of Bal Pharma Limited stock today?
One share of Bal Pharma Limited stock can currently be purchased for approximately $127.
-
When is Bal Pharma Limited's next earnings date?
Unfortunately, Bal Pharma Limited's (BALPHARMA.NS) next earnings date is currently unknown.
-
Does Bal Pharma Limited pay dividends?
Yes, Bal Pharma Limited pays dividends and its trailing 12-month yield is 0.98% with 0% payout ratio. The last Bal Pharma Limited stock dividend of $0 was paid on 6 Sep 2025.
-
How much money does Bal Pharma Limited make?
Bal Pharma Limited has a market capitalization of 1.96B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.63% to 3.39B US dollars.
-
What is Bal Pharma Limited's stock symbol?
Bal Pharma Limited is traded on the NSE under the ticker symbol "BALPHARMA.NS".
-
What is Bal Pharma Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Bal Pharma Limited?
Shares of Bal Pharma Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bal Pharma Limited's key executives?
Bal Pharma Limited's management team includes the following people:
- Mr. Shailesh Dheerajmal Siroya MD & Executive Director(age: 59, pay: $10,200,000)
- Mr. Himesh Virupakshaya Whole Time Director(age: 64, pay: $3,050,000)
-
How many employees does Bal Pharma Limited have?
As Jul 2024, Bal Pharma Limited employs 869 workers.
-
When Bal Pharma Limited went public?
Bal Pharma Limited is publicly traded company for more then 19 years since IPO on 8 May 2006.
-
What is Bal Pharma Limited's official website?
The official website for Bal Pharma Limited is balpharma.com.
-
How can i contact Bal Pharma Limited?
Bal Pharma Limited can be reached via phone at +91 80 4137 9500.
Bal Pharma Limited company profile:
Bal Pharma Limited
balpharma.comNSE
868
Drug Manufacturers - Specialty & Generic
Healthcare
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
Bengaluru, 560052
:
ISIN: INE083D01012
CUSIP: Y0553Q114
